Table 3 Crude and adjusted odds ratios for DKD development
Total | Subject developed DKD | Subject did not develop DKD | Unadjusted (95 % CI) | Adjusteda (95 % CI) | P-value | |
|---|---|---|---|---|---|---|
(N = 418) | (N = 30) | (N = 388) | ||||
No treatment | 136(100 %) | 16(11.8 %) | 120(88.2 %) | 1.00(reference) | 1.00(reference) | |
Non-RAS treatment | 11(100 %) | 2(18.2 %) | 9(81.8 %) | 1.67(0.33 to 8.41) | 2.40(0.43 to 13.48) | 0.366 |
RAS-treatment | 271(100 %) | 12(4.4 %) | 259(95.6 %) | 0.35(0.16 to 0.83) | 0.37(0.16 to 0.83) | 0.015 |